University of Oklahoma Receives $2.9M NCI Grant for Opaganib Trials

The grant will fund Phase 1b/2 trials of RedHill’s opaganib after CAR T therapy in ultra-high-risk multiple myeloma. RedHill is expected to supply the drug.